Coloron TissueGene Shares Plunge 20.28% on July 16 Ahead of TG-C Phase 3 Results

According to Korea Exchange, Coloron TissueGene shares fell 20.28% on July 16 ahead of the company's Phase 3 clinical trial announcement for osteoarthritis treatment TG-C. The stock dropped from 77,900 Korean won to 62,100 won, with intraday lows reaching 56,600 won (down 27.35%). The company stated it will announce Phase 3 results this month and confirmed data compilation is ongoing, making result leaks structurally impossible. Analysts note that even if structural improvement fails in Phase 3, FDA approval as a pain relief treatment remains possible, given existing therapies on the market.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments